Mankind Pharma

Which are the latest news on Mankind Pharma?

Why is Mankind Pharma Ltd falling/rising?

As of 05-Sep, Mankind Pharma Ltd's stock price is at 2,328.55, down 0.7%, with a total decline of 2.16% over the last two days. Despite strong fundamentals, the stock has underperformed its sector and benchmark, with a significant drop in investor participation indicating reduced confidence.

As of 05-Sep, Mankind Pharma Ltd's stock price is falling, currently at 2,328.55, reflecting a decrease of 16.45 (-0.7%). The stock has underperformed its sector by 0.25% today and has experienced a consecutive decline over the last two days, resulting in a total drop of 2.16% during this period. <BR><BR>In terms of performance over various time frames, the stock has seen a decline of 2.47% over the past week and 5.38% over the past month, while it has also fallen by 9.26% over the past year. Although the year-to-date performance shows a positive return of 6.02%, this is contrasted by the stock's underperformance relative to the benchmark Sensex, which has decreased by 10.21% year-to-date.<BR><BR>Additionally, there has been a notable drop in investor participation, with delivery volume on September 3 falling by 78.22% compared to the 5-day average. This decline in trading activity may indicate reduced interest or confidence among investors, contributing to the stock's downward movement. <BR><BR>While the company maintains strong fundamentals, such as high management efficiency and healthy long-term growth metrics, these positive factors are currently overshadowed by the recent price declines and falling investor engagement.

Who are in the management team of Mankind Pharma?

The management team of Mankind Pharma includes Ramesh Chand Juneja (Chairman), Rajeev Juneja (Vice Chairman & Managing Director), Sheetal Arora (CEO), and several independent directors, all of whom guide the company's strategic direction and operations.

The management team of Mankind Pharma includes the following key individuals:<BR><BR>1. **Ramesh Chand Juneja** - Chairman & Wholetime Director<BR>2. **Rajeev Juneja** - Vice Chairman & Managing Director<BR>3. **Sheetal Arora** - Whole Time Director & CEO<BR>4. **Tilokchand Punamchand Ostwal** - Independent Director<BR>5. **Pradeep Chugh** - Company Secretary & Compliance Officer<BR>6. **Bharat Anand** - Independent Director<BR>7. **Satish Kumar Sharma** - Whole-time Director<BR>8. **Vivek Kalra** - Independent Director<BR>9. **Vijaya Sampath** - Independent Director<BR><BR>This team plays a crucial role in guiding the company’s strategic direction and operations.

What does Mankind Pharma do?

Mankind Pharma Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹4,031 Cr and a net profit of ₹568 Cr for June 2026. It has a market cap of ₹97,343 Cr, a P/E ratio of 46.00, and a debt-equity ratio of 0.26.

Overview:<BR>Mankind Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Mankind Pharma Limited was incorporated in 1991 as a Private Limited Company and later converted to a Public Limited Company in 2005. The latest quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4,031 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 568 Cr (Quarterly Results - Jun 2026)<BR>- Market cap: INR 97,343 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 46.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 12.39%<BR>- Price to Book: 6.05<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Mankind Pharma?

Mankind Pharma's peers include Divi's Lab, Torrent Pharma, Zydus Lifesci, Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Aurobindo Pharma, and Glenmark Pharma. Notably, Laurus Labs has the highest 1-year return at 122.69%, while Mankind Pharma's return is -2.93%.

Peers: The peers of Mankind Pharma are Divi's Lab., Torrent Pharma, Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Aurobindo Pharma, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Divi's Lab., Zydus Lifesci., Cipla, Laurus Labs, Lupin, Dr Reddy's Labs, Glenmark Pharma, and the rest. Good growth is noted at Zydus Lifesci., Lupin, while Average growth is found at Torrent Pharma, Dr Reddy's Labs, Glenmark Pharma, and the rest. Excellent capital structure is seen at Divi's Lab., Zydus Lifesci., Cipla, Aurobindo Pharma, while Average capital structure is found at Laurus Labs, and the rest.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 122.69%, while Cipla has the lowest at -10.92%. Mankind Pharma's 1-year return is -2.93%, which is higher than Cipla's but lower than Laurus Labs'. Additionally, Dr Reddy's Labs and Lupin have negative six-month returns.

How big is Mankind Pharma?

As of 31st August, Mankind Pharma Ltd has a market capitalization of 97,343.00 Cr, with net sales of 14,737.88 Cr and a net profit of 2,042.67 Cr reported in the latest four quarters. The company has shareholder's funds of 16,300.34 Cr and total assets of 27,754.83 Cr as of March 2026.

As of 31st August, Mankind Pharma Ltd has a market capitalization of 97,343.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Mankind Pharma reported net sales of 14,737.88 Cr and a net profit of 2,042.67 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had shareholder's funds amounting to 16,300.34 Cr and total assets of 27,754.83 Cr.

Should I buy, sell or hold Mankind Pharma Ltd?

Are Mankind Pharma Ltd latest results good or bad?

Mankind Pharma Ltd's latest results show strong revenue growth, with net sales reaching ₹4,030.59 crores, a 17.07% increase sequentially and 12.89% year-on-year. However, declining operating and PAT margins due to rising costs raise concerns about sustainability in a competitive market.

Mankind Pharma Ltd's latest results present a mixed picture. On the positive side, the company achieved a significant milestone with net sales reaching ₹4,030.59 crores, marking a 17.07% sequential growth and a 12.89% increase year-on-year. This is the highest quarterly revenue in the company's history, indicating strong demand across its product portfolio.<BR><BR>Net profit also showed a positive trend, increasing by 2.47% quarter-on-quarter to ₹568.06 crores, and a notable 29.60% year-on-year growth. However, despite these impressive revenue and profit figures, the company faced challenges with margin compression. The operating margin decreased to 26.20%, down 81 basis points from the previous quarter, and the PAT margin contracted to 14.24%, reflecting rising costs, particularly in employee expenses.<BR><BR>Overall, while Mankind Pharma's revenue growth is commendable and demonstrates operational resilience, the declining margins raise concerns about sustainability in an increasingly competitive market. Investors may need to monitor how the company addresses these margin pressures moving forward.

When is the next results date for Mankind Pharma Ltd?

The next results date for Mankind Pharma Ltd is 30 July 2026.

The next results date for Mankind Pharma Ltd is scheduled for 30 July 2026.

Is Mankind Pharma technically bullish or bearish?

As of December 1, 2025, the technical trend has shifted to a bearish stance, driven by bearish MACD and Bollinger Bands signals, despite a bullish weekly RSI, with the stock trading below its previous close and well off its 52-week high.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and a bearish moving average on the daily timeframe. The weekly RSI is bullish, but this is overshadowed by the overall bearish trend in other indicators. The KST is mildly bearish, and there is no clear trend indicated by Dow Theory or OBV. Overall, the bearish sentiment is reinforced by the recent price action, with the stock trading below its previous close and significantly off its 52-week high.

How has been the historical performance of Mankind Pharma?

Mankind Pharma has shown consistent growth, with net sales increasing from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025, alongside rising profits and improved cash flow. Total assets surged from INR 6,323.62 crore to INR 27,651.64 crore during the same period.

Answer:<BR>The historical performance of Mankind Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Mankind Pharma's net sales have increased significantly from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 6,214.43 crore in March 2021 to INR 12,207.44 crore in March 2025. The total expenditure, excluding depreciation, also grew from INR 4,566.33 crore in March 2021 to INR 9,189.51 crore in March 2025, indicating rising operational costs. Operating profit (PBDIT) has shown a positive trend, climbing from INR 1,819.05 crore in March 2021 to INR 3,554.72 crore in March 2025. Profit before tax increased from INR 1,679.93 crore in March 2021 to INR 2,504.09 crore in March 2025, while profit after tax rose from INR 1,281.35 crore to INR 1,994.35 crore during the same period. The company's total assets surged from INR 6,323.62 crore in March 2021 to INR 27,651.64 crore in March 2025, with total liabilities also increasing from INR 6,323.62 crore to INR 8,483.03 crore. The cash flow from operating activities improved from INR 1,137 crore in March 2021 to INR 2,413 crore in March 2025, reflecting enhanced operational efficiency. Overall, Mankind Pharma has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and cash flow.

Is Mankind Pharma overvalued or undervalued?

As of October 13, 2025, Mankind Pharma is considered very expensive with a PE ratio of 53.30 and significant underperformance compared to peers and the Sensex, indicating it may be overvalued.

As of 13 October 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on key financial ratios, including a PE ratio of 53.30, an EV to EBITDA of 33.50, and a Price to Book Value of 7.06. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Mankind Pharma's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 34.9, while Cipla is valued attractively with a PE of 23.43. The disparity in valuations raises concerns about Mankind's sustainability at these levels. Furthermore, the company's stock has underperformed against the Sensex, with a year-to-date return of -15.1% compared to the Sensex's gain of 5.36%. This underperformance further supports the conclusion that Mankind Pharma is currently overvalued.

Who are the top shareholders of the Mankind Pharma?

The top shareholder of Mankind Pharma is the Ramesh Juneja Family Trust, holding 20.2%. Promoters own the majority, with institutional investors holding 20.59% combined, while individual investors own about 1.64%.

The top shareholders of Mankind Pharma include the Ramesh Juneja Family Trust, which holds the largest stake at 20.2%. The company is primarily owned by its promoters, with no pledged promoter holdings reported. Additionally, institutional investors are involved, with 32 mutual fund schemes holding a combined 7.67% and 554 foreign institutional investors (FIIs) holding 12.92%. The highest public shareholder is the SBI Large & Midcap Fund, which holds 1.58%. Individual investors collectively own about 1.64% of the company.

Has Mankind Pharma declared dividend?

No Dividend History Available